5
Orphan Designations
0 approved, 4 designated
0
FDA Approvals
0
Active Trials
10
Rare Diseases
across 21 areas
0
News (30d)
Quiet
Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc. is a company with 5 orphan drug designations across 10 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| acute lymphoblastic leukemia | a humanized anti-CD3/CD19 bispecific antibody | Des.TrialAppr. |
| adult acute lymphoblastic leukemia | a humanized anti-CD3/CD19 bispecific antibody | Des.TrialAppr. |
| childhood acute lymphoblastic leukemia | a humanized anti-CD3/CD19 bispecific antibody | Des.TrialAppr. |
| combined small cell lung carcinoma | vibostolimab and pembrolizumab | Des.TrialAppr. |
| follicular lymphoma | recombinant humanized anti-CD3/CD19 bispecific antibody | Des.TrialAppr. |
| folliculotropic mycosis fungoides | recombinant humanized anti-CD3/CD19 bispecific antibody | Des.TrialAppr. |
| lymphoma, non-Hodgkin, familial | recombinant humanized anti-CD3/CD19 bispecific antibody | Des.TrialAppr. |
| non-small cell squamous lung carcinoma | vibostolimab and pembrolizumab | Des.TrialAppr. |
| small cell lung carcinoma | vibostolimab and pembrolizumabTri-specific T cell activating construct targeting DLL3, HSA, and CD3e | Des.TrialAppr. |
| systemic sclerosis | Homodimeric fragment crystallizable (Fc) fusion protein comprised of the extracellular domain (ECD) of the human transforming growth factor beta receptor type II (TGFbetaRII) linked to a human IgG1 Fc domain | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
38
overlap in 2+ diseases
0/10
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
38
overlap in 2+ diseases
0/10
candidate diseases
0
avg importance: 0
0
affecting portfolio